Inactive Instrument

Aerpio Pharmaceuticals

Equities

ARPO

US00810B1052

Aerpio Pharmaceuticals, Inc. Appoints Stephen Hoffman, M.D., Ph.D., as Chief Executive Officer, Effective December 1, 2017

November 13, 2017 at 06:30 pm IST

Aerpio Pharmaceuticals, Inc. announced that the company strengthened senior leadership team with the appointment of Stephen Hoffman, M.D., Ph.D., as Chief Executive Officer Effective December 1, 2017.

Latest news about Aerpio Pharmaceuticals

Aadi Bioscience Completes Merger With Aerpio Pharmaceuticals; Shares Decline on Nasdaq Debut	27/21/27	MT
Aerpio Pharmaceuticals, Inc.(NasdaqCM:ARPO) dropped from NASDAQ Composite Index	27/21/27	CI
Aadi Bioscience, Inc. completed the acquisition of Aerpio Pharmaceuticals, Inc. in a reverse merger transaction.	26/21/26	CI
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	12/21/12	CI
North American Morning Briefing : Stock Futures -3-	09/21/09	DJ
AERPIO PHARMACEUTICALS : HC Wainwright Upgrades Aerpio Pharmaceuticals to Buy from Neutral on 'Transformative' Aadi Merger, Sets $22 Price Target	08/21/08	MT
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	17/21/17	CI
Aerpio Pharmaceuticals : Earnings Flash (ARPO) AERPIO PHARMACEUTICALS Reports Q1 Loss $-0.09	17/21/17	MT
Aerpio Pharmaceuticals : Aadi Bioscience to Merge Into Combined Listed Company	17/21/17	MT
Aadi Bioscience, Inc. agreed to acquire Aerpio Pharmaceuticals, Inc. in a reverse merger transaction.	17/21/17	CI
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	11/21/11	CI
Aerpio Pharmaceuticals Continues to Evaluate Strategic Alternatives	11/21/11	CI
Aerpio Pharmaceuticals : Quantum Leap Healthcare to Discontinue Testing of Aerpio Pharmaceutical's Razuprotafib in COVID Trial	05/21/05	MT
Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’S Razuprotafib in I-Spy Covid Trial	05/21/05	CI
Aerpio Pharmaceuticals, Inc. Plans to Terminate Kevin Peters as Chief Scientific Officer and Chief Medical Officer	02/21/02	CI
After Hours Watch List Scorecard: ISR, TATT, ARPO	07/21/07	MT
Aerpio Pharmaceuticals Announces Strategic Review After Topline Results from Razuprotafib Glaucoma Phase 2 Trial	06/21/06	CI
MT Newswires After Hours Watch List: ISR, TATT, ARPO	06/21/06	MT
Aerpio Pharmaceuticals : Pharma Starts Strategic Review To Boost Shareholder Value	06/21/06	MT
Aerpio Pharmaceuticals, Inc. Announces Strategic Review After Topline Results from Razuprotafib Glaucoma Phase 2 Trial	06/21/06	CI
AERPIO PHARMACEUTICALS : HC Wainwright Adjusts Aerpio Pharmaceuticals' Price Target to $1.50 From $2, Keeps at Neutral	14/20/14	MT
Aerpio Pharmaceuticals, Inc. Announces Topline Results from Razuprotafib Glaucoma Phase 2 Trial	12/20/12	CI
Transcript : Aerpio Pharmaceuticals, Inc., Q3 2020 Earnings Call, Nov 10, 2020	10/20/10
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	10/20/10	CI
Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19	27/20/27	CI

Chart Aerpio Pharmaceuticals

Duration

Period

More charts

Company Profile

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Its lead product candidate is razuprotafib. Razuprotafib, is a small molecule VE-PTP inhibitor, an enzyme that is upregulated in diabetic eye disease and that is responsible for inactivating Tie2. The Company is also developing a bispecific antibody that binds both VEGF and VE-PTP, which is designed to inhibit VEGF activation and activate Tie2. The Company's pipeline includes Razuprotafib (AKB-9778) Open Angle Glaucoma, Razuprotafib Acute Respiratory Distress Syndrome (ARDS)/ COVID-19, Razuprotafib Diabetic Kidney Disease, ARP-1536 Retinopathy/Nephropathy and Bispecific Ab Retinopathy/Cancer.

Sector

More about the company